Gene therapy for peripheral arterial disease

Molecular Medicine Today

Volumn 6, Issue 7, 2000, Pages 285-291

  Mann, Michael J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; DACRON; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; MESSENGER RNA; POLITEF; RIBOZYME; TRANSCRIPTION FACTOR; VASCULOTROPIN;

ARTERY DISEASE; ARTERY INTIMA PROLIFERATION; DACRON IMPLANT; DISEASE COURSE; GENE THERAPY; GRAFT FAILURE; HUMAN; IN VIVO STUDY; MINIMALLY INVASIVE SURGERY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POLITEF IMPLANT; RESTENOSIS; REVIEW; VEIN GRAFT;

ANGIOPLASTY; BIOCOMPATIBLE MATERIALS; CORONARY ARTERY BYPASS; CORONARY DISEASE; GENE THERAPY; GRAFT OCCLUSION, VASCULAR; HUMANS; HYPERPLASIA; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL VASCULAR DISEASES;

EID: 0033918344     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(00)01738-X     Document Type: Review

References (42)

1. Dzau V.J.et al. Vascular biology and medicine in the 1990s. Scope, concepts, potentials, and perspectives Circulation. 87:1993;705-719.
2. Braun-Dullaeus R.C.et al. Cell cycle progression. new therapeutic target for vascular proliferative disease Circulation. 98:1998;82-89.
3. Dzau V.J.et al. Future horizons in cardiovascular molecular therapeutics. Am. J. Cardiol. 80:1997;33I-39I.
4. Varley A.W., Mumford R.S. Physiologically responsive gene therapy. Mol. Med. Today. 4:1998;445-451.
5. Zaug A.et al. The Tetrahymena ribozyme acts like an RNA restriction endonuclease. Nature. 324:1986;429-433.
6. Bielinska A.et al. Regulation of gene expression with double-stranded phosphothioate oligonucleotides. Science. 250:1990;997-1000.
7. Ross R. Cell biology of atherosclerosis. Annu. Rev. Physiol. 57:1995;791-804.
8. Walker L.N.et al. Production of platelet-derived growth factor-like molecules by cultured arterial smooth muscle cells accompanies proliferation after arterial injury. Proc. Natl. Acad. Sci. U. S. A. 83:1986;7311-7315.
9. Warner S.J.C., Libby P. Human vascular smooth muscle cells. Target for and source of tumor necrosis factor. J. Immunol. 142:1989;100-109.
10. Morishita R.et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. U. S. A. 90:1993;8474-8478.
11. Simons M.et al. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature. 359:1992;67-70.
12. Shi Y.et al. Transcatheter delivery of c-myc antisense oligomers reduce neointimal formation in a porcine model of coronary artery balloon injury. Circulation. 90:1994;944-951.
13. Burgess T.L.et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by nonantisense mechanism. Proc. Natl. Acad. Sci. U. S. A. 92:1995;4051-4055.
14. Morishita R.et al. A novel molecular strategy using cis element 'decoy' of E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci. U. S. A. 92:1995;5855-5859.
15. Chang M.W.et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 267:1995;518-522.
16. Chang M.W.et al. Adenovirus-mediated over-expression of the cyclin/cyclin dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J. Clin. Invest. 96:1995;2260-2268.
17. Indolfi C.et al. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat. Med. 1:1995;541-545.
18. Von der Leyen H.E.et al. Gene therapy inhibiting neointimal vascular lesion. in vivo gene transfer of endothelial-cell nitric oxide synthase gene Proc. Natl. Acad. Sci. U. S. A. 92:1995;1137-1141.
19. Varenne O.et al. Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation. 98:1998;919-926.
20. Ohno T.et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science. 265:1994;781-784.
21. Pollman M.J.et al. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat. Med. 4:1998;222-227.
22. Isner J.M.et al. Clinical protocol. arterial gene therapy for restenosis Hum. Gene Ther. 7:1996;989-1011.
23. Laitinen M.et al. Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. Hum. Gene Ther. 9:1998;1481-1486.
24. Cox J.L.et al. Stranger in a strange land. the pathogenesis of saphenous vein graft stenosis Prog. Cardiovasc. Dis. 34:1991;45-68.
25. Mann M.J.et al. Genetic engineering of vein grafts resistant to atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 92:1995;4502-4506.
26. Mann M.J.et al. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J. Clin. Invest. 99:1997;1295-1301.
27. Mann M.J.et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy. the PREVENT single-centre, randomised, controlled trial Lancet. 354:1999;1493-1498.
28. Mann M.J. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc. Natl. Acad. Sci. U. S. A. 96:1999;6411-6416.
29. Chen S.-J.et al. Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. Circulation. 89:1994;1922-1928.
30. Kupfer J.M.et al. High efficiency gene transfer to autologous rabbit jugular vein grafts using adenovirus-transferrin/polylysine-DNA complexes. Hum. Gene Ther. 5:1994;1437-1443.
31. George S.J.et al. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther. 5:1998;1552-1560.
32. Bai H.et al. Inhibition of intimal hyperplasia after vein grafting by in vivo transfer of human senescent cell-derived inhibitor-1 gene. Gene Ther. 5:1998;761-769.
33. Schwartz L.B. Adenoviral-mediated gene transfer of a constitutively active form of the retinoblastoma gene product attenuates neointimal thickening in experimental vein grafts. J. Vasc. Surg. 29:1999;874-881.
34. Herring M.B. Endothelial cell seeding. J. Vasc. Surg. 13:1991;731-732.
35. Wilson J.M.et al. Implantation of vascular grafts lined with genetically modified endothelial cells. Science. 244:1989;1344-1346.
36. Dunn P.F.et al. Seeding of vascular grafts with genetically modified endothelial cells. Secretion of recombinant TPA results in decreased seeded cell retention in vitro and in vivo. Circulation. 93:1996;1439-1446.
37. Folkman J.et al. Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. 133:1971;275-288.
38. Ware J.A., Simons M. Angiogenesis in ischemic heart disease. Nat. Med. 3:1997;158-164.
39. Banai S.et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation. 89:1994;2183-2189.
40. Folkman J., Klagsburn M. Angiogenic factors. Science. 235:1987;442-447.
41. Tabata H. Arterial gene transfer of acidic fibroblast growth factor for therapeutic angiogenesis in vivo. critical role of secretion signal in use of naked DNA Cardiovasc. Res. 35:1997;470-479.
42. Baumgartner I. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 97:1998;1114-1123.